The Point of Care (POC) Diagnostics Market is witnessing significant growth, driven by technological advancements, increasing research applications, and rising demand for personalized medicine. A recent report by We Market Research Insights provides an in-depth analysis of this evolving sector, covering market size, trends, competitive landscape, and future opportunities.
The Point of Care (POC) Diagnostics Market is poised for substantial growth between 2025 and 2035, fueled by the increasing prevalence of infectious diseases and continuous technological advancements. Valued at approximately USD 49.6 billion in 2025, the market is projected to surge to USD 118.2 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.2% over the decade.
Request Sample Copy: https://wemarketresearch.com/reports/request-free-sample-pdf/point-of-care-diagnostics-market/1679
Key Players:
F. Hoffmann-La Roche Ltd.
Qiagen
Danaher Corporation
Becton Dickinson (BD)
bioMérieux
Abbott
Siemens Healthcare GmbH
Werfen
Nova Biomedical
Trividia Health, Inc.
QuidelOrtho Corporation
Trinity Biotech
Sekisui Diagnostics
Orasure Technologies, Inc.
EKF Diagnostics Holdings plc.
Market Growth and Key Drivers
The growing demand for rapid and efficient diagnostic solutions is a key factor propelling market expansion. POC diagnostics enable immediate patient care by allowing testing to be conducted in diverse settings, including doctor's offices, ambulances, homes, remote areas, and hospitals.
Several factors contribute to this market's growth:
Rising Prevalence of Chronic and Infectious Diseases
The incidence of diseases such as diabetes, rheumatism, and cancer is increasing globally due to factors like an aging population, sedentary lifestyles, poor dietary habits, and environmental influences.
Technological Advancements
Innovations in portable diagnostic devices and the integration of telemedicine are making point-of-care testing more accessible and efficient. These advancements facilitate real-time health monitoring and timely interventions, improving patient outcomes.
Global Health Initiatives and Government Support
International health organizations are emphasizing the need for quick and effective diagnostic solutions. For instance, in December 2022, the World Health Organization (WHO) reported that malaria remained a significant global health challenge, with 247 million cases recorded in 2021. Increased investments in rapid diagnostic tests for infectious diseases continue to drive market growth.
Market Segmentation
By Test Type:
Glucose Testing
HbA1c Testing
Coagulation Testing
Fertility & Pregnancy Testing
Infectious Disease Testing
Thyroid Stimulating Hormone (TSH) Testing
Hematology Testing
Urinalysis & Kidney Function Testing
Cancer Marker Testing
Comments
0 comment